News and Information

Biofourmis Names Two Pharmaceutical Veterans to Leadership Team

BOSTON, Aug. 22, 2019 /PRNewswire/ — Biofourmis, a fast-growing global leader in digital therapeutics based in Boston, has added two global pharmaceutical senior executive veterans to its executive team to guide the company’s worldwide expansion across the pharmaceutical, managed care, healthcare provider and medical technology markets.

Read More

Biofourmis in the Beckers’ List of Top 100 AI Companies to Know in Healthcare

Biofourmis offers a powerful patented AI-based platform for therapeutic decision support. It continuously analyzes data from medical-grade wearable sensors and other patient-generated data to create unique digital biomarkers reflecting the health status of an individual. These digital biomarkers have been assessed in several studies and have demonstrated the ability to help detect changes in an individual’s health status much earlier than previously possible.

Read More

Everion a cornerstone in major new Biofourmis trial at Yale University-Mayo Clinic

In collaboration with the FDA and our partner Biofourmis, Biovotion’s Everion will play a critical role in a new trial aimed at improving outcomes and evaluating new endpoints for heart failure patients. Leveraging Biofourmis’ AI-enabled platform, BiovitalsHF, data collected from discharged patients will be used to develop new methods of evaluating the efficacy of heart failure drugs.

Read More

Digital therapeutics leader Biofourmis to take part in pioneering heart failure research with Yale University-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI)

BOSTON, July 16, 2019 /PRNewswire/ — Biofourmis, a fast-growing global leader in digital therapeutics, has entered a research partnership with the Yale University-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI). Biofourmis’ mobile platform BiovitalsHFTM will be leveraged in a study of patients with heart failure to monitor functional capacity and quality of life to see if greater emphasis should be placed on these measures in the drug approval process.

Read More

FDA Contributes to Hunt for New Heart Failure Endpoints

A collaboration involving the FDA is set to evaluate new endpoints for heart failure clinical trials. The partners will use wearable devices to assess how heart failure patients function and feel after being discharged from hospitals.

Read More

Foreign start-ups eye China’s vast digital health care market, but finding the right revenue model holds the key to success

Start-ups such as Boston-based Biofourmis have partnered with local health care platforms like Jianke, giving the company access to its vast customer base…

Read More

25 Machine Learning Startups To Watch In 2019

Biofourmis is a fast-growing global digital health tech start-up that is reinventing remote patient monitoring by combining AI, machine learning…

Read More

AI-enabled monitoring, decision support platform Biofourmis raises $35M

Biofourmis, a Singapore-based startup pioneering a distinctly tech-based approach to the treatment of chronic conditions, has raised a $35 million Series B round for expansion.

The round was led by Sequoia India and MassMutual Ventures, the VC fund from Massachusetts Mutual Life Insurance Company. Other investors who put in include EDBI, the corporate investment arm of Singapore’s Economic Development Board, China-based healthcare platform Jianke and existing investors Openspace Ventures, Aviva Ventures and SGInnovate, a Singapore government initiative for deep tech startups. The round takes Biofourmis to $41.6 million raised to date, according to Crunchbase.

Read More

FDA Clears Biofourmis’ Software for ECG-based Arrhythmia Detection

The RhythmAnalytics platform can integrate with medical devices and other ECG management systems to detect arrhythmias.

Read More

Biofourmis CEO has Been Invited to Milken Institute’s Young Leader’s Circle

Our CEO and Co-Founder Kuldeep Singh Rajput was recently honoured with an invitation to join Milken Institute’s Young Leader’s Circle (continue)

Read More

Biofourmis’ RhythmAnalytics outperforms Cardiologist and State of Art Deep Learning Techniques for Arrhythmia Detection

We’re proud to say that our deep learning platform for ECG interpretation, RhythmAnalytics, outperforms a human analysis of an ECG with a high degree of accuracy! (continue)

Read More

Biofourmis CEO Entered into Forbes Asia 30 under 30 (Health Care)

Congratulations to our Founder and CEO Kuldeep Singh Rajput for making it into the Forbes Asia 30 Under 30 list for Healthcare and Science 2019! We’re excited to celebrate this well-deserved achievement as we continue on our mission to predict and prevent critical medical events before they happen!

Read More

Whether you are a healthcare provider,
payer or pharmaceutical,
biofourmis empowers you

Get In Touch